Pages that link to "Q36914078"

The following pages link to Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia (Q36914078):

Displaying 34 items.

• Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia (Q24642439) (← links)
• Molecular allelokaryotyping of T-cell prolymphocytic leukemia cells with high density single nucleotide polymorphism arrays identifies novel common genomic lesions and acquired uniparental disomy (Q33417186) (← links)
• Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial (Q33439818) (← links)
• Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion: a retrospective analysis of prognostic factors in China (Q33649977) (← links)
• The clinical application of monoclonal antibodies in chronic lymphocytic leukemia (Q34310845) (← links)
• LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients (Q34924406) (← links)
• Employment of oligodeoxynucleotide plus interleukin-2 improves cytogenetic analysis in splenic marginal zone lymphoma (Q35001307) (← links)
• p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy (Q35597328) (← links)
• Patients with chronic lymphocytic leukaemia (CLL) differ in the pattern of CTLA-4 expression on CLL cells: the possible implications for immunotherapy with CTLA-4 blocking antibody (Q36834544) (← links)
• FISH Analysis for del6q21 and del17p13 in B-cell Chronic Lymphocytic Leukemia in Iranians. (Q36839266) (← links)
• De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience (Q37028638) (← links)
• CTLA-4 affects expression of key cell cycle regulators of G0/G1 phase in neoplastic lymphocytes from patients with chronic lymphocytic leukaemia (Q37143869) (← links)
• Clinical application of array-based comparative genomic hybridization for the identification of prognostically important genetic alterations in chronic lymphocytic leukemia (Q37273662) (← links)
• Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway (Q37434174) (← links)
• Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance (Q37588785) (← links)
• From pathogenesis to treatment of chronic lymphocytic leukaemia (Q37643423) (← links)
• Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk (Q37659388) (← links)
• Clinicobiologic importance of cytogenetic lesions in chronic lymphocytic leukemia (Q37810096) (← links)
• DNA methylation of tumor suppressor miRNA genes: a lesson from the miR-34 family (Q37962577) (← links)
• Retinoblastoma and the genetic theory of cancer: an old paradigm trying to survive to the evidence (Q40171441) (← links)
• Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics (Q43200452) (← links)
• Cytogenetic characterisation in Chinese patients with chronic lymphocytic leukemia: a prospective, multicenter study on 143 cases analysed with interphase fluorescence in situ hybridisation (Q43509833) (← links)
• Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia. (Q46013515) (← links)
• Defining 'medical necessity' in an age of personalised medicine: A view from Canada (Q48069953) (← links)
• Frequency and functional characterization of exhausted CD8+ T cells in chronic lymphocytic leukemia. (Q48110651) (← links)
• Monosomy 12 and deletion of 13q34 in a case of chronic lymphocytic leukemia with concomitant lung cancer (Q48332552) (← links)
• Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays. (Q50790201) (← links)
• More (on) prognostic factors in chronic lymphocytic leukemia (Q57243442) (← links)
• Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis (Q58001012) (← links)
• The autocrine motility factor receptor is overexpressed on the surface of B cells in Binet C chronic lymphocytic leukemia (Q59487755) (← links)
• Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways (Q59797169) (← links)
• Chromosomal abnormalities detected by multicolor fluorescence in situ hybridization in fine-needle aspirates from patients with small lymphocytic lymphoma are useful for predicting survival (Q81748285) (← links)
• Atypical 11q deletions identified by array CGH may be missed by FISH panels for prognostic markers in chronic lymphocytic leukemia (Q83214944) (← links)
• Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study (Q90465397) (← links)